# NT Asset

> NT Asset is a VC fund backing Content, Genetics and Software. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Nov 2021
- Lead investor: 67%
- Last updated: Aug 2026

NT Asset is a VC fund focused on Content and Genetics. NT Asset

## Contacts

5 contacts available for NT Asset. Shizune tracks 1 team members at NT Asset. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/nt-asset?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Content | 1 | 33% |
| Genetics | 1 | 33% |
| Software | 1 | 33% |
| Messaging | 1 | 33% |
| Compliance | 1 | 33% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |
| Series B | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 1 | 33% |
| United Kingdom | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Kenneth Ng | Partner | 0 | https://shizune.co/investors/profile/kenneth-ng |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Geneoscopy | Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $105M | Series B | Nov 16, 2021 |  |
| Geneoscopy | Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $6.9M | Series A | Oct 02, 2019 |  |
| Pushfor | Pushfor is a secure content sharing and instant messaging platform, designed for enterprises, that converts and projects content in high fidelity to any device. We have a patented smart approach to delivering content of any type or size - whereby the content is not sent to the device but ‘pushed’ in real time without the file leaving its sourcelocation. Content delivery is highly secure and tightly controlled with customizable viewing permissions combined with real-time tracking, full audit trail and usage analytics. Users have immediate and easy access, and can interactively engage with content by instant chat messaging, anytime, anywhere from their preferred device and without the need of any authoring software. | $1.6M | Seed | Nov 23, 2016 |  |

3 of 3 investments shown.

## Co-investors
- [Cultivation Capital](https://shizune.co/investors/profile/cultivation-capital) — VC Fund, 2 deals together
- [Lightchain](https://shizune.co/investors/profile/lightchain) — VC Fund, 2 deals together
- [BioGenerator](https://shizune.co/investors/profile/biogenerator) — VC Fund, 1 deal together
- [c12 Ventures](https://shizune.co/investors/profile/c12-ventures) — VC Fund, 1 deal together
- [Innovatus Capital Partners](https://shizune.co/investors/profile/innovatus-capital-partners) — VC Fund, 1 deal together
- [LabCorp](https://shizune.co/investors/profile/laboratory-corporation-of-america) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does NT Asset invest in?

NT Asset invests primarily in Content, Genetics and Software startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact NT Asset?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at NT Asset?

The team at NT Asset includes Kenneth Ng (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co